Pulsatile drug-delivery systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 18, Issue 5, 2001, Pages 433-458

  Bussemer, T ^a   Otto, I ^a   Bodmeier, R ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Oral drug delivery; Pulsatile drug delivery systems

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; DEXAMETHASONE; DRUG; ENZYME; ETHYL CELLULOSE; ETHYLENE VINYL ACETATE COPOLYMER; EUDRAGIT; FAMOTIDINE; GLUCOCORTICOID; HYDROXYPROPYLMETHYLCELLULOSE; INSULIN; LACTOSE; MESALAZINE; MICROCRYSTALLINE CELLULOSE; MORPHINE; PEPTIDE; POLITEF; POLYLACTIC ACID; POLYSORBATE 80; PREDNISOLONE; PROPOLIS; RANITIDINE; SALAZOSULFAPYRIDINE; STARCH GLYCOLATE SODIUM; UNINDEXED DRUG; VASOPRESSIN;

CHRONOPHARMACOLOGY; CONTROLLED DRUG RELEASE; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG PELLET; FIRST PASS EFFECT; HUMAN; MEMBRANE PERMEABILITY; NONHUMAN; PH; PRESSURE; PULSATILE DRUG RELEASE; REVIEW; TIME;

EID: 0035209251     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v18.i5.10     Document Type: Review

References (107)

1. Formulation approaches for oral pulsatile drug delivery
2. Chronopharmacokinetics: Implications for drug treatment
3. Eines neues therapieprincip bei nächtlichen asthma
4. Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer
5. Pharmacodynamics of intravenous ranitidine after bolus and continuous infusion in patients with healed duodenal ulcers
6. The influence of patient characteristics on the requirements for postoperative analgesia. A reassessment using patient-controlled analgesia
7. Chronopharmacology: A review of drugs studied
8. Why are so many biological systems periodic?
9. Circadian variation in gastric emptying of meals in humans
10. Colon drug delivery
11. Targeted delivery in den gastrointestinaltrakt
12. Gastric emptying and small and large bowel transit of non-disintegrating tablets in fasted subjects
13. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery
14. Gastric emptying of indigestible tablets in relation to composition and time of ingestion of meals studied by metal detector
15. Inflammatory bowel disease
16. A new approach to the oral administration of insulin and other peptide drugs
17. Insulin and the gastrointestinal tract
18. Development and in vitro/in vivo evaluation of a colonic release capsule of vasopressin
19. Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa
20. The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools
21. Coated 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis
22. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting
23. An in vivo investigation into the suitability of pH-dependent polymers for colonic targeting
24. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device
25. Very low intraluminal colonic pH in patients with active ulcerative colitis
26. Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD)
27. Azo polymers for colon-specific drug delivery
28. Use of azo polymers for colon-specific drug delivery II: Influence of the type of azo-polymer on the degradation by intestinal microflora
29. Use of azo polymers for colon-specific drug delivery
30. Azo reduction is mediated by enzymatically generated low molecular weight electron carriers
31. Pectin/chitosan mixtures as coatings for colon-specific drug delivery, an in vitro evaluation
32. Development and characterization of water soluble dextran fatty acid esters as excipient for colon-targeting
33. Lauroyldextran as a coating material for site-specific drug delivery to the colon: In vitro dissolution of coated pellets
34. Design of microencapsulated chitosan microspheres for colonic drug delivery
35. Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon
36. β-Cyclodextrin matrix films for colon-specific drug delivery
37. Amylose as a coating for drug delivery to the colon: Preparation and in vitro evaluation using 5-aminosalicylic acid pellets
38. 13 glucose microspheres as a model for drug delivery to the colon
39. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs
40. New preparation method of intestinal pressure-controlled colon delivery capsules by coating machine and evaluation in beagle dogs
41. A dissolution test for a pressure-controlled colon delivery capsule: Rotating basket method
42. A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract
43. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers
44. Oral delayed-release system for colonic specific delivery
45. Oral chronotopic drug delivery systems: Achievement of time and/or site specifity
46. Evaluation of low viscosity HPMC as retarding coating material in the preparation of a time-based oral colon specific delivery system
47. Chronotopic system, influence of various HPMC grades as coating agents on the release behaviour
48. Low viscosity HPMC coating of soft and hard gelatin capsules for delayed and colonic release: Preliminary investigations on process parameters and in vitro release performances
49. Controlled drug release of highly water-soluble pentoxifylline from time-limit disintegration-type wax matrix tablets
50. Pulsatile release from laminated methylhydroxypropyl cellulose matrices with KC1 as model drug
51. A new ibuprofen pulsed release oral dosage form
52. Ibuprofen delayed release dosage forms: A proposal for the preparation of an in vitro/in vivo pulsatile system
53. Delivery device for the release of the active ingredient in subsequent times
54. In vitro evaluation of a potential colonic delivery system that releases drug after a controllable lag time
55. Enteric coated timed release systems for colonic targeting
56. The Time Clock system: A new oral dosage form for fast and complete release of drug after a predetermined lag time
57. Floating or pulsatile drug delivery systems based on coated effervescent cores
58. Konzept und entwicklung einer arzneiform mit pulsartiger wirkstoff-freigabe nach einer steuerbaren und pH-unabhängigen latenzzeit
59. A generic protein delivery system based on osmotically rupturable monoliths
60. Pulsatile drug release from coated capsules
61. Development of oral controlled release preparations, a PVA swelling controlled release system (SCRS). I. Design of SCRS and its release controlling factor
62. Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation
63. The tolerability of multiple oral doses of Pulsincap® capsules in healthy volunteers
64. The design and evaluation of controlled release systems for the gastrointestinal tract
65. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug
66. Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system
67. Programmable oral release technology, Port systems: A novel dosage form for time and site specific oral drug delivery
68. A novel programmable oral release technology for delivering drugs: Human feasibility testing using gamma scintigraphy
69. Voraussetzung für die entwicklung einer sinnvollen retardund diuretikakombination
70. Development of a novel drug release system, time-controlled explosion system (TES). I. Concept and design
71. Development of a novel drug release system, time-controlled explosion system (TES). II. Design of multi-particulate TES and in vitro drug release properties
72. Development of a novel drug release system, time-controlled explosion system (TES). III. Relation between lag time and membrane thickness
73. Development of a novel drug delivery system (TES): V. Animal pharmacodynamic study and human bioavailability study
74. A new multiparticulate delayed release system. Part I: Dissolution properties and release mechanism
75. A new multiparticulate delayed release system. Part II: Coating formulation and properties of free films
76. Mechanism of pellet coat rupture and its effect on drug release
77. Design of capsules that burst at predetermined times by dialysis
78. The influence of buffer species and strength on diltiazem HCl release from beads coated with aequeous cationic polymer dispersions, Eudragit RS, RL 30D
79. An organic acid-induced sigmoidal release system for oral controlled-release preparations
80. An organic acid-induced sigmoidal release system for oral controlled-release preparations. 2. Permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid
81. Drug release behavior in gastrointestinal tract of beagle dogs from multiple-unit-type rate-controlled or time-controlled release preparations coated with insoluble polymer-based film
82. Pulsed drug release with film coatings of Eudragit RS30D